HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stefano Barabino Selected Research

Stefano Barabino Research Topics

Disease

28Dry Eye Syndromes (Dry Eye Syndrome)
10/2022 - 03/2003
13Inflammation (Inflammations)
07/2022 - 02/2002
2Keratitis
01/2019 - 12/2016
2Corneal Injuries
01/2019 - 07/2010
2Pterygium
11/2008 - 05/2008
2Keratoconjunctivitis Sicca
09/2008 - 03/2003
2Benign Mucous Membrane Pemphigoid (Cicatricial Pemphigoid)
03/2003 - 02/2003
1Pathologic Dilatation (Ectasia)
01/2019
1Keratoconus
01/2019
1Cataract (Cataracts)
01/2016
1Autoimmune Diseases (Autoimmune Disease)
01/2016
1Wounds and Injuries (Trauma)
01/2015
1Meibomian Gland Dysfunction
03/2011
1Neuromyelitis Optica (Devic's Disease)
03/2010
1Corneal Neovascularization
06/2007
1Disease Progression
11/2005
1Hereditary Corneal Dystrophies
05/2005
1Hyperemia
02/2005
1Type I Plasminogen Deficiency
04/2004
1Hepatitis B
03/2003
1Cicatrix (Scar)
03/2003
1Rheumatoid Arthritis
03/2003
1Syphilis
03/2003

Drug/Important Bio-Agent (IBA)

7HLA-DR Antigens (HLA-DR)IBA
07/2022 - 02/2002
6Fluorescein (Funduscein)FDA LinkGeneric
07/2022 - 03/2003
6Lubricant Eye Drops (Artificial Tears)IBA
02/2022 - 06/2009
4LipidsIBA
02/2022 - 09/2008
4Ophthalmic Solutions (Eye Drops)IBA
01/2021 - 01/2019
3Cyclosporine (Ciclosporin)FDA LinkGeneric
10/2022 - 12/2016
3EmulsionsIBA
01/2021 - 07/2010
3Hyaluronic Acid (Hyaluronan)IBA
11/2020 - 07/2010
3Scopolamine (Hyoscine)FDA Link
01/2019 - 07/2010
2Loteprednol Etabonate (Alrex)FDA Link
07/2022 - 01/2019
2Biological ProductsIBA
02/2022 - 05/2021
2Pharmaceutical PreparationsIBA
02/2022 - 12/2016
2Proteins (Proteins, Gene)FDA Link
05/2021 - 03/2011
2SolutionsIBA
01/2019 - 07/2010
2Interleukin-6 (Interleukin 6)IBA
01/2019 - 02/2008
2AntigensIBA
11/2011 - 06/2007
2Omega-6 Fatty Acids (Omega 6 Fatty Acids)IBA
11/2011 - 02/2008
1SuspensionsIBA
07/2022
1ElectrolytesIBA
02/2022
1AntioxidantsIBA
02/2022
1Surface-Active Agents (Surfactants)IBA
02/2022
1lifitegrastIBA
11/2021
1InflammasomesIBA
05/2021
1hylanIBA
11/2020
1CytokinesIBA
06/2019
1Anti-Infective Agents (Microbicides)IBA
01/2019
1CollagenIBA
01/2019
1AtropineFDA LinkGeneric
01/2019
1Hydrocortisone (Cortisol)FDA LinkGeneric
01/2019
1Interleukin-8 (Interleukin 8)IBA
01/2019
1TNF-Related Apoptosis-Inducing LigandIBA
01/2019
1Anti-Bacterial Agents (Antibiotics)IBA
01/2019
1Concanavalin AIBA
01/2019
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2019
1Fatty Acids (Saturated Fatty Acids)IBA
11/2017
1HCEIBA
01/2017
1MethylprednisoloneFDA LinkGeneric
12/2016
1Phenolsulfonphthalein (Phenol Red)IBA
12/2016
1Toll-Like Receptors (Toll-Like Receptor)IBA
05/2015
1Estrogens (Estrogen)FDA Link
10/2014
1Benzalkonium Compounds (Benzalkonium Chloride)FDA LinkGeneric
09/2014
1Bimatoprost (Lumigan)FDA Link
09/2014
1Polysaccharides (Glycans)IBA
03/2014
1Retinaldehyde (Retinal)IBA
03/2010
1Propylene Glycol (1,2 Propanediol)FDA LinkGeneric
06/2009
1hydroxypropyl guarIBA
06/2009
1polyethylene glycol 400IBA
06/2009
1LubricantsIBA
06/2009
1Linoleic Acid (Linoleate)IBA
02/2008
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
02/2008
1Interleukin-2 (IL2)IBA
02/2008
1Interferon-gamma (Interferon, gamma)IBA
02/2008
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2008
1Interleukin-10 (Interleukin 10)IBA
02/2008
1alpha-Linolenic Acid (Linolenic Acid)IBA
02/2008
1IntegrinsIBA
06/2007
1Integrin alpha1beta1IBA
06/2007
1Immunomodulating AgentsIBA
11/2005
1Polyglactin 910IBA
03/2003
1gamma-Linolenic AcidIBA
03/2003
1SilkFDA Link
03/2003
1Histocompatibility Antigens Class IIIBA
03/2003

Therapy/Procedure

9Therapeutics
11/2021 - 02/2002
3Transplantation
04/2004 - 02/2003
2Refractive Surgical Procedures
01/2019 - 01/2016
2Contact Lenses
01/2016 - 02/2005
2Corneal Transplantation (Keratoplasty)
06/2007 - 05/2005
1Topical Administration
01/2019
1Corneal Cross-Linking
01/2019
1Diet Therapy (Therapy, Diet)
11/2017
1Laser In Situ Keratomileusis (LASIK)
01/2015
1Transdermal Patch
07/2010
1Slit Lamp
11/2008
1Immunotherapy
06/2007
1Keratectomy
05/2005
1Sutures (Suture)
03/2003
1Cesarean Section (Caesarean Section)
03/2003